Roche

Roche. It is a global pioneer in pharmaceuticals and diagnostics, operating under a unified model to drive personalized healthcare. Founded in Basel, the company has grown into one of the world's largest biotechnology companies and a leading provider of in vitro diagnostics. Its operations are divided into two core segments: Pharmaceuticals and Diagnostics, with a longstanding commitment to research-driven innovation.

History

The company was established in 1896 by Fritz Hoffmann-La Roche, who envisioned a standardized, industrial-scale production of medicines. An early breakthrough came with the production of the antitussive Sirolin and the introduction of the sedative Pantopon. The firm expanded internationally before World War I, establishing subsidiaries in the United States and Germany. A significant early achievement was the industrial synthesis of vitamin C, marketed as Redoxon, which became a major commercial success. During the 1930s, the company developed the first sulfonamide antibacterial, Prontosil, marking its entry into antibiotics. The post-war era saw expansion through acquisitions, including the purchase of Laboratoires Français de Chimiothérapie in 1958. The late 20th century was defined by a strategic shift towards biotechnology, notably with the 1990 acquisition of a majority stake in Genentech, a move that transformed the industry. Further consolidation of its diagnostics division occurred through the 1998 merger with Boehringer Mannheim and the 2014 purchase of the remaining stake in Foundation Medicine.

Business operations

The company's activities are segmented into Pharmaceuticals and Diagnostics, headquartered at its main site in Basel. The Pharmaceuticals division focuses on developing medicines in key therapeutic areas including oncology, immunology, infectious diseases, and ophthalmology. The Diagnostics division, a world leader in in vitro diagnostics, operates through centralized and point-of-care testing solutions under brands like cobas and VENTANA. Geographically, operations span the globe, with major regional hubs in North America, Europe, and Asia-Pacific. Key international affiliates include Genentech in South San Francisco and Chugai Pharmaceutical in Tokyo, over which it holds a controlling stake. The company maintains a vast manufacturing and supply network, with major production facilities in Basel, Penzberg, and Vacaville, California.

Products and pipelines

The company's portfolio includes major therapeutic blockbusters and diagnostic systems. In oncology, key products include the monoclonal antibodies rituximab (MabThera/Rituxan), trastuzumab (Herceptin), and bevacizumab (Avastin). Other significant pharmaceutical products encompass the multiple sclerosis therapy ocrelizumab (Ocrevus), the hemophilia treatment emicizumab (Hemlibra), and the age-related macular degeneration drug ranibizumab (Lucentis). The diagnostics portfolio features the cobas systems for molecular diagnostics and clinical chemistry, and the VENTANA platform for anatomic pathology. The research pipeline is robust, with numerous compounds in late-stage clinical trials across neuroscience, with drugs like gantenerumab for Alzheimer's disease, and continued innovation in cancer immunotherapy and gene therapy.

Research and development

Research and development is the cornerstone of the company's strategy, with annual investment consistently ranking among the highest in the industry. This work is conducted through a network of internal research centers and external collaborations. Key R&D sites include the Basel headquarters, the Genentech Research and Early Development (gRED) unit in South San Francisco, and the Pharmaceutical Research and Early Development (pRED) organization in Europe. Major collaborative partnerships have been formed with institutions like the Broad Institute and companies such as Adaptive Biotechnologies. The focus areas for discovery span oncology, neuroscience, immunology, and infectious diseases, with a strong emphasis on leveraging biomarkers and companion diagnostics to enable personalized treatment approaches.

Corporate affairs

The company is incorporated as a publicly traded Aktiengesellschaft under Swiss law and is a constituent of the Swiss Market Index. Its governance structure includes a Board of Directors chaired by Christoph Franz and an Executive Committee led by CEO Thomas Schinecker. It has faced significant legal and regulatory challenges, including antitrust investigations related to vitamin price fixing in the 1990s and ongoing patent litigation concerning biologics like trastuzumab. The corporate philosophy emphasizes long-term value creation and sustainability, with commitments outlined in its annual Corporate Responsibility Report. Its corporate citizenship initiatives are channeled through the Roche Foundation and include major access programs for medicines in low-income countries and support for humanitarian organizations like the World Health Organization.

Category:Pharmaceutical companies of Switzerland Category:Companies listed on the SIX Swiss Exchange Category:Biotechnology companies